Zepbound vials go on sale for pickup at Walmart pharmacies

Eli Lilly and Walmart announced on Oct. 29, 2025, that Zepbound (tirzepatide) single-dose vials sold at LillyDirect's cash-pay prices can be picked up at Walmart pharmacies, the first time a LillyDirect direct-to-consumer price has been available at a retail counter instead of only by mail ^[1][5]. Walmart, which has nearly 4,600 pharmacies nationwide, will offer the vials in all approved strengths, with the companies saying the option will be available nationwide "by mid-November" ^[1][2].

What the prices are

The self-pay prices are the same whether a patient chooses free home delivery from LillyDirect or pickup at Walmart: $349 per month for the 2.5 mg starting dose, and $499 per month for 5 mg, 7.5 mg, 10 mg, 12.5 mg and 15 mg ^[1][2]. There is a condition on the higher-dose price. To get $499 a month for doses above 5 mg, patients "must meet the requirements for the Zepbound Self Pay Journey Program," which Lilly describes as designed to support continuity of care and access, "subject to applicable terms and conditions" ^[1][4]. The sources do not spell out what those requirements are, so exactly who qualifies is not yet known from this announcement.

Lilly says the prices are open to anyone with a valid, on-label Zepbound prescription, regardless of insurance status, and that its self-pay pricing is "a 50% or greater discount compared to the list price of other incretin (GLP-1) medicines for obesity" ^[1][2]. That comparison is Lilly's own framing against competitors' list prices, not against what any individual pays after insurance or coupons.

How the ordering works

The route is not a normal walk-in. Prescriptions have to be sent to LillyDirect Self Pay Pharmacy Solutions through a prescriber's electronic health record system; at checkout, the patient picks either free LillyDirect home delivery or pickup at a Walmart pharmacy ^[1][2]. Walmart's pharmacy chief, Kevin Host, framed it as convenience: "Life is busy, and this will help people discover new, easy ways to get their medication" ^[1][2].

The product on offer is the single-dose vial, not the autoinjector pen. Vials require the user to draw the dose with a syringe, and the announcement covers all approved strengths ^[1][5].

The cash channel is already a large share of Lilly's business. In the second quarter of 2025, about 35% of new Zepbound prescriptions were filled through LillyDirect's self-pay option, according to the company ^[1][2]. Reuters characterized that figure as cash-paying customers and noted Lilly is competing with Novo Nordisk's Wegovy (semaglutide) for a share of what it called a potential $150 billion obesity drug market ^[5].

Why it matters for patients

For people paying cash — because they have no GLP-1 coverage, were denied prior authorization, or lost coverage mid-year — this adds a pickup option at a price that was previously mail-order only ^[1][5]. That can matter for anyone who wants same-day handoff from a pharmacist, has had shipping or temperature-control problems with mail delivery, or lives somewhere package theft is a concern.

It also changes very little for people whose insurance already covers Zepbound at a lower copay. The self-pay price is a separate track from insurance; the announcement says the prices apply regardless of insurance status, but it does not say self-pay purchases count toward a deductible or out-of-pocket maximum, and the sources do not address that ^[1][2].

Two practical uncertainties remain. First, the higher-dose $499 price is tied to program requirements that the announcement does not detail ^[1][4]. Second, the companies describe nationwide rollout "by mid-November," which means availability at a specific store on a given day is not guaranteed by the Oct. 29 announcement ^[1][2]. Whether individual Walmart locations will stock vials consistently is not addressed in the sources.

Zepbound is approved for adults with obesity, or some adults with overweight plus weight-related medical problems, and for moderate-to-severe obstructive sleep apnea with obesity; it is meant to be used with a reduced-calorie diet and increased physical activity ^[1][2]. Lilly's labeling warns it should not be used with other tirzepatide products or any GLP-1 receptor agonist, and carries a boxed warning about thyroid C-cell tumors ^[1][2].

What happens next

• Oct. 29, 2025: Lilly and Walmart announce the collaboration ^[1][2][5].
• By mid-November 2025: Pickup expected at Walmart pharmacies nationwide ^[1][2].

Lilly says it "will continue to explore additional options to broaden patient access" ^[1][2]. Whether other chains follow is not stated.